© 2026 Forbes Media LLC. All Rights Reserved.
© 2026 Forbes Media LLC. All Rights Reserved.
Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results